Skip to content

Clinical trials

Coronary Disease trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Coronary Disease Country / region: United States Clear all

271 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20006
20016
200211
20038
200413
200511
200622
200716
200813
200917
201015
20117
201217
201312
201412
20154
20168
20177
20184
20199
20206
20212
20221
20232
20246
20254
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed214
Terminated20
Unknown status11
Active, not recruiting10
Recruiting8
Withdrawn5
Suspended1
Not yet recruiting1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Heart, Lung, and Blood Institute (NHLBI)23
Abbott Medical Devices14
CardioDx11
Johns Hopkins University10
Washington University School of Medicine8
Hoffmann-La Roche7
Duke University6
Abbott5
Brigham and Women's Hospital5
University of Chicago5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Coronary Disease271
Coronary Artery Disease94
Cardiovascular Diseases88
Heart Diseases58
Myocardial Ischemia44
Atherosclerosis33
Myocardial Infarction25
Angina Pectoris23
Vascular Diseases22
Arteriosclerosis20

Trials

Showing 1 to 25 of 271. Each trial links to its page on Pharma Observatory.

171 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.